Caitlin Costello, MD, discusses the role and safety of bispecific antibodies approved for the treatment of relapsed/refractory multiple myeloma as well as emerging data and clinical trials with this treatment approach.

Listen as Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss the diagnosis and typical presenting symptoms of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as findings from recent phase III studies including NETTER-2 and CABINET. Notable clinical pearls regarding GEP-NET therapies and current guidelines for GEP-NET care and monitoring are also highlighted.

Audio podcast with key clinical highlights for gynecologic cancers from the 2024 ESMO congress. Listen to experts put new trial results into context and share their perspectives and takeaway points for integrating new data into your everyday practice.

Listen to expert perspectives on selecting optimal therapy for patients with CLL, with a focus on how BTK inhibitor resistance mutations are assessed and how they affect therapy choice.

Audio podcast with highlights from a live webinar covering available clinical data and approved treatments options for progressive ROS1-altered advanced non-small-cell lung cancer (NSCLC), including emerging options on the horizon. Listen to the experts review and discuss their perspectives and summarize the clinical data in support of guideline second-line and beyond treatments.

Audio podcast with highlights from a live webinar covering available clinical data and approved treatments for ROS1-altered TKI-naive advanced non-small-cell lung cancer (NSCLC). Listen to the experts review and discuss their perspectives and summarize clinical data in support of guideline-recommended first-line treatment approaches.

Audio podcast with clinical highlights from a live webinar covering current recommended molecular testing for ROS1-alterations in patients with non-small-cell lung cancer. Listen to the experts review and discuss their perspectives and summarize current best practices.

Audio podcast with key clinical midyear highlights for gynecologic cancer from the 2024 SGO annual meeting on women’s cancer and the 2024 ASCO annual meeting. Listen to experts put new trial results into context and cover practical perspectives and takeaway points for your everyday practice.

In this podcast based on a live symposium at the American Society of Clinical Oncology 2024 Annual Meeting, 3 experts discuss the current data and use of SERDs for patients with HR+/HER2- breast cancer.

Listen to Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how they align their clinical practice with the NCCN guidelines in the management of their patients with CLL/SLL.

Audio podcast with key clinical highlights for myeloproliferative neoplasms from the 2024 ASCO annual meeting and the EHA 2024 Congress. Listen to an expert analysis of new trial results with an emphasis on practical perspectives and summarizing the relevant clinically important takeaway points for everyday practice.

Listen to Julio C. Chavez, MD, MS, a medical oncologist based in an academic center, and Alan Skarbnik, MD, a medical oncologist based in the community, discuss the emerging role of CELMoDs in non-Hodgkin lymphoma care, including available data and ongoing clinical trials with these agents.

In this podcast based on a live symposium at the American Society of Clinical Oncology 2024 Annual Meeting, 3 experts discuss the role of CDK4/6 inhibitors in the adjuvant and metastatic setting for HR-/HER2- breast cancer.

Audio podcast with key clinical highlights for acute myeloid leukemia from the 2024 ASCO annual meeting and the EHA 2024 Congress. Listen to an expert analysis of new trial results with an emphasis on practical perspectives and summarizing the relevant clinically important takeaway points for everyday practice.

Audio podcast with key clinical highlights for myelodysplastic syndromes from the 2024 ASCO annual meeting and the EHA 2024 Congress. Listen to an expert analysis of new trial results with an emphasis on practical perspectives and summarizing the relevant clinically important takeaway points for everyday practice.

Listen as a medical oncologist, pharmacist, and nurse practitioner discuss their experiences with oral SERDs for the treatment of hormone receptor–positive, HER2-negative, metastatic breast cancer, including how to manage adverse events and ways to promote treatment adherence and persistence.

Listen in as Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the CLL guidelines from the NCCN and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes.

Listen to this podcast featuring a multidisciplinary discussion between Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, for expert guidance on optimal biomarker testing to guide treatment decisions in advanced prostate cancer.

Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer.

In this podcast, Rebecca S. Heist, MD, MPH, discusses the safety profile and management of potential adverse events associated with HER3-directed therapies in lung cancer.